Natera Impresses with Milestones in the Signatera Cancer Test!

Natera (NTRA, i) is an exciting diagnostics company that is likely to achieve trend continuation with several pivotal points in its favor. The company specializes in ctDNA-based tests in oncology (Signatera), women's health (Panorama), and organ health (Prospera). The core product, Signatera, enables the detection of minimal residual disease (MRD) in cancer patients and is increasingly being used as a companion diagnostic for therapy decisions. This opens up new growth opportunities. In mid-May, FDA approval was granted for Signatera CDx as a companion...